Works matching IS 10538569 AND DT 2020 AND VI 29 AND IP 10
Results: 22
Assessing the impact of unmeasured confounders for credible and reliable real‐world evidence.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1219, doi. 10.1002/pds.5117
- By:
- Publication type:
- Article
Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1279, doi. 10.1002/pds.5108
- By:
- Publication type:
- Article
Using real‐world evidence to support a changing paradigm for cancer screening: A commentary.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1312, doi. 10.1002/pds.5104
- By:
- Publication type:
- Article
Real‐world effectiveness of pembrolizumab in previously treated non‐small cell lung cancer: A population‐based cohort study.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1295, doi. 10.1002/pds.5091
- By:
- Publication type:
- Article
Understanding when real world data can be used to replicate a clinical trial: A cross‐sectional study of medications approved in 2011.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1273, doi. 10.1002/pds.5086
- By:
- Publication type:
- Article
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1263, doi. 10.1002/pds.5065
- By:
- Publication type:
- Article
Allopurinol‐induced severe cutaneous adverse drug reactions: Risk minimization measures in Malaysia.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1254, doi. 10.1002/pds.5033
- By:
- Publication type:
- Article
Real‐world data in Saudi Arabia: Current situation and challenges for regulatory decision‐making.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1303, doi. 10.1002/pds.5025
- By:
- Publication type:
- Article
The effect of an intervention program on the knowledge and attitudes among medical staff regarding adverse drug reaction reporting.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1246, doi. 10.1002/pds.5013
- By:
- Publication type:
- Article
Considerations when evaluating real‐world data quality in the context of fitness for purpose.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1316, doi. 10.1002/pds.5010
- By:
- Publication type:
- Article
Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1236, doi. 10.1002/pds.5006
- By:
- Publication type:
- Article
Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1336, doi. 10.1002/pds.5005
- By:
- Publication type:
- Article
Conducting prospective sequential surveillance in real‐world dynamic distributed databases.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1331, doi. 10.1002/pds.5002
- By:
- Publication type:
- Article
Translational hurdles with cannabis medicines.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1325, doi. 10.1002/pds.4999
- By:
- Publication type:
- Article
Using real‐world safety data in regulatory approval decisions: Sotagliflozin and the risk of diabetic ketoacidosis.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1322, doi. 10.1002/pds.4994
- By:
- Publication type:
- Article
What types of real‐world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1307, doi. 10.1002/pds.4992
- By:
- Publication type:
- Article
Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1228, doi. 10.1002/pds.4975
- By:
- Publication type:
- Article
Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1213, doi. 10.1002/pds.4962
- By:
- Publication type:
- Article
Trial designs using real‐world data: The changing landscape of the regulatory approval process.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1201, doi. 10.1002/pds.4932
- By:
- Publication type:
- Article
Using cancer registries to supplement clinical trial data and inform regulatory decision.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1319, doi. 10.1002/pds.4931
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1341, doi. 10.1002/pds.4831
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2020, v. 29, n. 10, p. 1, doi. 10.1002/pds.4949
- Publication type:
- Article